Xenetic Biosciences (XBIO) AI Stock Analysis

• Market Cap: $5.80M
• Dividend Yield: N/A
• Average Volume (3M): 1.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 13.30%
• EPS Growth: 22.70%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 2,291,056
• 10 Day Avg. Volume: 5,053,508
• 30 Day Avg. Volume: 1,695,238
• PEG Ratio: 0.30
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -0.08
• Enterprise Value/Gross Profit: -0.08
• Enterprise Value/Ebitda: 0.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.32
• Revenue Forecast (FY): $3.00M

• Rating: 42 Neutral
• Price Target: $2.50 ▲(13.12% Upside)
• Action: Reiterated Date: 01/10/26
• Date: Action: Reiterated 01/10/26

The score is held down primarily by persistent losses and negative free cash flow alongside a shrinking equity cushion, with weak technical trend and negative MACD reinforcing downside risk. Low/no debt and improving revenue provide some support, but valuation remains challenged due to lack of profitability, and the delayed annual meeting adds a modest governance overhang.

Positive Factors

Conservative leverage (no debt)

Zero reported debt is a durable financial strength: it lowers fixed obligations and bankruptcy risk, preserving optionality to fund R&D through equity, partnerships or milestone deals. This structural flexibility supports continued investment in clinical programs without near-term debt servicing.

Top-line improvement

Sustained revenue growth (~17% TTM) indicates improving commercial or collaboration receipts and validates program progress. Durable revenue momentum helps extend runway, supports incremental R&D spend, and reduces absolute reliance on external financing if continued over coming quarters.

Focused oncology R&D pipeline

A clear focus on oncology and DNMT1-targeted programs aligns with structural demand for novel cancer therapies. For a biotech, a specialized pipeline creates potential high-value milestones, partner interest, and licensing opportunities that can materially alter long-term cash flows when clinical progress is achieved.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow (~-$2.7M TTM) is a durable weakness: ongoing cash burn erodes liquidity, forces reliance on external capital, and increases dilution risk. Without material revenue scaling or financing, this constrains multi-quarter execution of clinical programs.

Ongoing net losses and negative margins

Sustained net losses and deeply negative margins show the cost base far exceeds current revenue. This structural profitability gap means the company cannot self-fund growth, heightening dependency on financings or partnerships and raising execution risk until margins materially improve.

Governance / shareholder engagement issues

Repeated adjournments for lack of quorum signal weak shareholder engagement and governance frictions. This can delay critical approvals, impede timely strategic or financing actions, and create an overhang that complicates long-term planning and counterparty confidence in partnerships or capital raises.

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

How the Company Makes Money

Xenetic Biosciences makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves licensing its technologies to pharmaceutical partners, thereby earning milestone payments and royalties on the sales of drugs developed using its platforms. Xenetic also engages in collaborations and strategic partnerships to co-develop therapies, which may include upfront payments, research funding, and shared revenues from successful products. Additionally, the company may receive government grants and funding to support its research initiatives.

Xenetic Biosciences Financial Statement Overview

Summary

Revenue improved to ~$2.86M (+16.9% TTM), and debt is effectively $0, but the business remains loss-making (~-$3.16M net loss) with negative operating/free cash flow (~-$2.72M TTM). The shrinking equity base (~$18.4M in 2021 to ~$4.0M TTM) increases dilution/liquidity risk if cash burn persists.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved to ~$2.86M (+16.9% growth), showing some top-line momentum. However, profitability remains weak: net income is still a loss (~-$3.16M) and margins are deeply negative, indicating the cost base is far larger than current revenue. Losses have narrowed versus earlier years, but the business is not yet near break-even.

Balance Sheet

Leverage looks conservative with total debt at $0 in the most recent periods (and minimal historically), which reduces financial risk. That said, the equity base has declined meaningfully over time (from ~$18.4M in 2021 to ~$4.0M in TTM), consistent with ongoing losses and raising the risk of future dilution or tighter liquidity if cash burn continues.

Cash Flow

Cash generation is a key weakness: TTM (Trailing-Twelve-Months) operating cash flow is negative (~-$2.72M) and free cash flow is also negative (~-$2.72M), indicating the company is still consuming cash to operate. While cash burn has improved versus 2022–2023 levels, free cash flow remains consistently below zero, leaving the funding outlook dependent on external capital unless operations improve materially.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.86M	2.50M	2.54M	1.71M	1.16M	436.94K
Gross Profit	2.86M	2.50M	2.54M	1.71M	1.16M	436.94K
EBITDA	-3.29M	-4.05M	-4.52M	-6.69M	-5.71M	-4.67M
Net Income	-3.16M	-3.96M	-4.13M	-6.55M	-5.65M	-10.89M
Balance Sheet
Total Assets	5.07M	6.90M	10.61M	14.72M	19.82M	13.18M
Cash, Cash Equivalents and Short-Term Investments	4.12M	6.17M	8.98M	13.10M	18.24M	11.53M
Total Debt	0.00	0.00	0.00	0.00	27.04K	62.52K
Total Liabilities	1.11M	894.26K	809.59K	1.07M	1.42M	963.97K
Stockholders Equity	3.96M	6.01M	9.80M	13.65M	18.39M	12.22M
Cash Flow
Free Cash Flow	-2.72M	-2.82M	-4.11M	-5.15M	-4.74M	-4.27M
Operating Cash Flow	-2.72M	-2.82M	-4.11M	-4.65M	-4.74M	-4.27M
Investing Cash Flow	0.00	0.00	0.00	-500.00K	0.00	0.00
Financing Cash Flow	0.00	0.00	0.00	0.00	11.45M	5.43M

Xenetic Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.21
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Neutral. The current price of 2.21 is below the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.26, and below the 200-day MA of 3.03, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 60.50 is Neutral, neither overbought nor oversold. The STOCH value of 87.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XBIO.

Xenetic Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	51 Neutral	$19.99M	-0.92	-70.67%	―	6.29%	7.42%
APRE	43 Neutral	$10.50M	-0.43	-74.72%	―	-62.75%	23.87%
HCWB	43 Neutral	$3.11M	-0.04	―	―	-87.93%	65.26%
XBIO	42 Neutral	$5.80M	-1.24	-57.43%	―	13.30%	22.70%

Xenetic Biosciences Corporate Events

Xenetic Biosciences faces ongoing delays in annual meeting

On December 11, 2025, Xenetic Biosciences, Inc. announced that its 2025 Annual Meeting of Stockholders, originally scheduled for that day, was adjourned until January 8, 2026 to achieve a quorum and allow more time to solicit proxies on behalf of the board. When the meeting reconvened on January 8, 2026, it was again adjourned without any business conducted due to the continued lack of a requisite quorum, and the company now plans to reconvene the meeting at a future, yet-to-be-determined date, signaling ongoing stockholder engagement and governance challenges that could delay corporate decision-making.

The most recent analyst rating on (XBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Xenetic Biosciences stock, see the XBIO Stock Forecast page.

Xenetic Biosciences Adjourns 2025 Annual Meeting

On December 11, 2025, Xenetic Biosciences announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum, with plans to reconvene on January 8, 2026. The adjournment allows additional time to solicit proxies, and stockholders who have not yet voted are encouraged to do so. The meeting will continue to be held virtually, and previously submitted votes remain valid unless revoked.